NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $5.40 -0.18 (-3.23%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.25▼$5.5950-Day Range$4.21▼$6.5852-Week Range$1.62▼$7.66Volume492,924 shsAverage Volume646,422 shsMarket Capitalization$303.77 millionP/E RatioN/ADividend YieldN/APrice Target$14.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Black Diamond Therapeutics alerts: Email Address Black Diamond Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside173.1% Upside$14.75 Price TargetShort InterestBearish10.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.09Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.42) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.97 out of 5 starsMedical Sector545th out of 910 stocksBiological Products, Except Diagnostic Industry86th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Black Diamond Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.68% of the outstanding shares of Black Diamond Therapeutics have been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Black Diamond Therapeutics has recently increased by 35.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDTX. Previous Next 3.4 News and Social Media Coverage News SentimentBlack Diamond Therapeutics has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Black Diamond Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for BDTX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.87% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Black Diamond Therapeutics are expected to grow in the coming year, from ($1.42) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Black Diamond Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Black Diamond Therapeutics Stock (NASDAQ:BDTX)Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More BDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDTX Stock News HeadlinesSeptember 7 at 1:13 AM | americanbankingnews.comHC Wainwright Weighs in on Black Diamond Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:BDTX)September 5 at 3:33 AM | americanbankingnews.comBlack Diamond Therapeutics (NASDAQ:BDTX) Given "Buy" Rating at HC WainwrightSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 5 at 1:45 AM | markets.businessinsider.comBuy Rating Reaffirmed for Black Diamond Therapeutics Amid Promising Clinical Trials and Solid FinancialsAugust 6, 2024 | markets.businessinsider.comBuy Rating on Black Diamond Therapeutics: Promising Early Results for BDTX-1535 in NSCLC TreatmentAugust 6, 2024 | globenewswire.comBlack Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateJune 1, 2024 | globenewswire.comBlack Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 29, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…May 22, 2024 | finance.yahoo.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the companyMay 10, 2024 | msn.comShould You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?May 9, 2024 | sfgate.comBlack Diamond: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comBlack Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 24, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 11, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Changes to Board of DirectorsApril 8, 2024 | finance.yahoo.comWall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should KnowApril 7, 2024 | globenewswire.comBlack Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual MeetingApril 3, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesSee More Headlines Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDTX CUSIPN/A CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$14.75 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+173.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,440,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.08% Return on Assets-51.68% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio6.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book2.76Miscellaneous Outstanding Shares56,253,000Free Float51,263,000Market Cap$303.77 million OptionableOptionable Beta2.49 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Mark A. Velleca M.D. (Age 60)Ph.D., CEO, President & Chairman Comp: $795.98kDr. David M. Epstein Ph.D. (Age 65)Co-Founder & Director Comp: $969.69kDr. Fang Ni Pharm.D. (Age 37)CFO, Principal Financial Officer and Chief Business Officer Comp: $665.98kDr. Sergey Yurasov M.D. (Age 55)Ph.D., Chief Medical Officer Comp: $718.92kDr. Elizabeth Buck Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Comp: $340.47kMr. Brent Hatzis-Schoch Esq. (Age 59)J.D., COO & General Counsel Comp: $683.29kMs. Elizabeth L. Montgomery (Age 52)Chief People Officer Ms. Melanie Morrison (Age 49)Chief Development Officer Ms. Erika Jones (Age 39)Senior VP of Finance & Corporate Controller More ExecutivesKey CompetitorsC4 TherapeuticsNASDAQ:CCCCInhibrxNASDAQ:INBXSpectrum PharmaceuticalsNASDAQ:SPPIAlectorNASDAQ:ALECCompugenNASDAQ:CGENView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 28,501 shares on 8/16/2024Ownership: 0.051%Affinity Asset Advisors LLCBought 650,000 shares on 8/15/2024Ownership: 1.155%The Manufacturers Life Insurance Company Bought 60,189 shares on 8/15/2024Ownership: 0.107%Marshall Wace LLPBought 94,537 shares on 8/14/2024Ownership: 0.168%Squarepoint Ops LLCSold 146,025 shares on 8/14/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.81 at the start of the year. Since then, BDTX shares have increased by 92.2% and is now trading at $5.40. View the best growth stocks for 2024 here. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) posted its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $151 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Black Diamond Therapeutics' major shareholders? Top institutional investors of Black Diamond Therapeutics include Ally Bridge Group NY LLC (1.48%), Affinity Asset Advisors LLC (1.16%), TD Asset Management Inc (0.47%) and Renaissance Technologies LLC (0.47%). Insiders that own company stock include Growth N V Biotech, Ali Behbahani, David M Epstein and Fang Ni. View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA) and Homology Medicines (FIXX). This page (NASDAQ:BDTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
